Study #16 · Chapter C
3% hypertonic salt in bronchiolitis in infants
Original title: Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis.
- Authors
- Avigdor Mandelberg, Guy Tal, Michaela Witzling, Eli Someck, Sion Houri
- Journal
- Chest
- Year
- 2003
Summary
The study examined nebulized 3% hypertonic saline in infants hospitalized with viral bronchiolitis. The treatment was evaluated for symptoms such as shortness of breath, mucus, and airway obstruction. The results indicate that hypertonic salt can help make mucus thinner and support breathing. In the context of hospitalized children, a shorter duration of illness or hospital stay was also described.
What was investigated
Nebulized 3% hypertonic saline solution was studied in infants admitted with viral bronchiolitis.
What were the findings
The research shows that nebulized 3% hypertonic salt can have beneficial effects in infants with viral bronchiolitis. The treatment can help thin mucus, clear the airways, and reduce shortness of breath. In hospitalized children, the literature also showed a shorter duration of illness or shorter hospital stay.
Why relevant for halotherapy
This study is relevant because it shows that salt application in young children with respiratory complaints can have an effect on mucus and breathing. Halotherapy also works via inhaled salt particles and follows the same principle: helping to clean the airways and better remove trapped mucus.
Original publication
Avigdor Mandelberg, Guy Tal, Michaela Witzling, Eli Someck, Sion Houri. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest, 2003.
pubmed.ncbi.nlm.nih.gov/12576370/This summary has been prepared for readability and does not replace the original scientific publication. Consult the source via the link for the full context. Halotherapy is a complementary approach to promoting health and does not replace medical treatment or advice from your treating physician.